Building an innovative platform to make clinical monitoring more accurate Shanghai, June 25, 2021 /PRNewswire/ -- How to treat cancer patients accurately? How to dynamically monitor the effect of treatment multiple times? How to avoid invasive testing? These issues are not only o

builds an innovative platform to make clinical monitoring more accurate

Shanghai, June 25, 2021 /PRNewswire/ -- How to accurately treat cancer patients? How to dynamically monitor the effect of treatment multiple times? How to avoid invasive testing? These issues are not only of concern to patients, but also to clinical expectations. How to continuously innovate in these fields to help human health? On June 23, the Huisuan Expert Workstation and the Big Health Technology R&D and Application Innovation Platform were unveiled in Shanghai. At the same time, the Huisuan MRD clinical research project was officially launched. The

smart computing expert workstation is led by Academician Guo Yike, a double academician of the European Academy of Sciences and the Royal Academy of Engineering, and Professor Li Yixue, director of the Biomedical Big Data Center of the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. It gathers clinical medicine, molecular genetics, big data, artificial intelligence, etc. A technological innovation and R&D platform in which many experts and professors participate.

The innovation platform was born at the right time

Li Hongming, member of the party group and first-level inspector of Shanghai Science and Technology Association, said in his speech that Shanghai Science and Technology Association is focusing on the strategic goals of building Shanghai Science and Technology Innovation Center, expert workstations and big health technology research and development and application. The establishment of the innovation platform comes at the right time. In recent years, under the influence of the global development trend of precision medicine, my country has intensively issued relevant policies in the field of precision medicine, providing policy guidance to accelerate the development of the industry. Precision medicine has become an important part of the country's strategic emerging industries. During the 14th Five-Year Plan period, with the promulgation of national health and medical big data standards, security and service management measures, more standards and supporting policies will be released in the field of medical big data. The precision medicine industry will continue to improve in policy, technology, market demand and capital. It has achieved rapid development driven by the combined efforts of many factors. Relying on the work carrier of the Shanghai Academician Expert Workstation, we will continue to promote the construction of a precise innovative service system.

She hopes that Huisuan will rely on expert workstations and big health technology R&D and application innovation platforms, with the guidance and help of academician Guo Yike, Professor Li Yixue and other scientific research teams, and actively build Shanghai's precision based on the principles of complementary advantages, cooperation, mutual trust, and common development. Diagnosis and treatment industry, jointly build a system of shared trust technology platforms, effectively integrate and exert the power of expert resources and technologies in the precision medicine industry, continuously strengthen the dominant position of corporate innovation, and take the lead in the construction of precision diagnosis and treatment and biomedical big data in Shanghai. effect.

The leaders of Shanghai Industrial Technology Research Institute also hope that Huisuan, which is one of the first batch of National Genetic Testing Technology Application Demonstration Centers and Genetic Testing Demonstration Centers for High-incidence Tumors and Hereditary Diseases under the National Development and Reform Commission, can undertake the related business of big data R&D and application innovation platform. It will be implemented to provide reasonable support for industrial technology research in Shanghai's construction of a science and technology innovation center with global influence, and to help the high-quality development of related industries in Shanghai and the Yangtze River Delta.

Liu Yonghui, full-time vice chairman of the Pudong New Area Science and Technology Association, Cao Xiaojing from the Innovation Service Department of the Shanghai Science and Technology Association, Xi Donghong, Party Branch Secretary and Deputy Director of Shanghai Pudong Activity Center, Academician of the Chinese Academy of Sciences in Pudong, Ni Fuhua, Director of the Academician Service Department, Innovation Service Department of the Pudong New Area Science and Technology Association Guo Jianping, Zhu Jiaying, academician of the Chinese Academy of Sciences, Shanghai Pudong Activity Center, Wu Junwei, president of the Shanghai Industrial Technology Research Institute, Ding Zhigang, party branch secretary, Wang Meng, director of the Innovation Service Center and other leaders have high hopes for the development of the innovation platform and hope that the expert workstation will provide strategic emerging industries in Pudong New Area. development and contribute to Shanghai's scientific and technological innovation development.

Tumor detection and monitoring are looking forward to new technologies

Academician Guo Yike made a remote video sharing. He believes that tumor data are complex and involve multi-omics information such as imaging, pathology, and molecular diagnosis. Data integration and efficient processing capabilities are needed to effectively analyze tumor pathogenic factors and related factors, and carry out targeted tumor research and prevention. In the field of medical research, big data can strengthen the integration of clinical information with molecular biology, genomics, metabolomics and other disciplines, discover disease mechanisms, and improve the efficacy of targeted drugs and immunotherapy. He hopes to establish a big data clinical research platform for tumors and share data to predict and evaluate the genetic status of tumor patients, providing a basis for personalized treatment for patients, hoping to help the clinic and patients.

Professor Li Yixue hopes that the smart computing expert workstation and innovation platform will collaborate across multiple disciplines, with artificial intelligence big data and precise diagnosis and treatment as the core, to create a leading technology platform with the purpose of better serving society. The four aspects advocated by the state: "facing the international scientific and technological frontiers", "facing the major national needs", "facing the main economic battlefield", and "facing the health of all people" are also the directions that guide the development of science and technology. Efforts to develop personalized cancer diagnosis and treatment technology are aimed at cancer patients, serving patients, and serving society. The Huishuan MRD clinical research project launched at the same time by

also aroused strong interest from the experts attending the meeting. Minimal residual disease (MRD) refers to the state in which a small number of cancer cells remain in the body of cancer patients after remission after treatment, which may eventually cause disease recurrence. MRD testing refers to testing the circulating tumor DNA (ctDNA) after surgery or after treatment after the patient has received radical treatment such as surgery and adjuvant therapy. Based on the ctDNA test results, it is determined whether there is any residue at the molecular level. lesions. For ctDNA monitoring, the patient's prognosis and efficacy prediction are evaluated through multiple dynamic detections of the patient's ctDNA content. Dynamic detection based on patient MRD can help clinicians provide more personalized and precise treatment to patients, which is different from traditional diagnosis and treatment paths, brings better clinical benefits to patients, and is expected to allow cancer patients to achieve long-term survival. At present, dynamic detection technology has been applied in the whole process of tumor management, covering early screening, perioperative period, late-stage personalized medication, recurrence monitoring, etc.

Increasing evidence shows that residual molecular-level tumor lesions in patients with solid tumors may lead to tumor recurrence after radical treatment, resulting in poor prognosis. However, current detection technologies and monitoring methods have obvious deficiencies in sensitivity and specificity, and there are few dimensions and markers that can be used in dynamic monitoring. Therefore, new technical means are needed to provide reliable tools for early clinical intervention earlier than conventional detection means (such as imaging). Non-invasive liquid biopsy technology provides new ideas for dynamic detection of treated tumor patients. During the MRD clinical research expert discussion after the launch ceremony of the

project, Professor Wang Liwei, Director of the Oncology Department of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Chairman of the Pancreatic Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), gave a speech on "Dynamic Monitoring of MRD Clinical Research Progress" "Special report", the person in charge of the expert workstation made a special introduction on "MRD detection technology research and product development progress". Afterwards, the participating experts conducted in-depth discussions on relevant issues. Experts hope that the smart computing expert workstation will rely on MRD clinical research projects to serve the national strategy, collaborate with multi-disciplinary experts, clinical experts, molecular genetics experts, big data analysis experts, and cooperate with relevant biomedical companies to create multi-faceted technology upgrades and promote the industry Technical specifications and innovative developments.

Huisuan helps the future of precision diagnosis and treatment of tumors

Huisuan Medical has a systematic and complete scientific research hardware foundation and a R&D technical team with reasonable structure and complementary knowledge, and has built a professional precision diagnosis and treatment experimental technology platform and real-time updated precision diagnosis and treatment knowledge. Interpretation system and excellent laboratory quality management system; developed a series of gene sequencing data analysis algorithms, gene-disease-drug-efficacy and other related precise diagnosis and treatment knowledge interpretation, semantic retrieval, machine learning and other algorithm systems, and also built a reporting automation system, The whole process management system has formed a lot of intellectual property rights; Huishuan has been working in the precision diagnosis and treatment scientific research service industry for several years, and its business scope covers more than 20 provinces and cities across the country, with good channel markets and terminal resources. The project to be carried out by the Huisuan Expert Workstation is MRD and dynamic monitoring technology for minimal residual disease based on big data and artificial intelligence technology, which dynamically monitors the patient's risk of recurrence through the detection of circulating tumor cell ctDNA in the blood. The main technical difficulties in MRD at present are: first, accurately selecting as many detection sites as possible, which requires the help of big data and artificial intelligence technology; second, more accurate experimental technology, algorithms and knowledge bases are needed to support each other, which requires us to continue Upgrade, optimize experimental processes, and conduct in-depth analysis of models and knowledge bases.Deng Xiyin, CEO of

Huishuan, introduced that the Huishuan Expert Workstation, under the leadership of Academician Guo and Professor Li, will give full play to the advantages of the expert team in big data, artificial intelligence algorithms, and biological information analysis modeling to explore and verify multi-dimensional detection solutions, including Gene mutation, methylation, circulating tumor cells, imaging, etc., develop more optimized bioinformatics analysis algorithms, personalized testing plan recommendation algorithms, and establish a tumor burden prediction model based on multi-dimensional features, which will more effectively distinguish between detection background noise and weak signals to improve detection sensitivity and specificity. In the future, MRD can also be combined with artificial intelligence to form a precise diagnosis and treatment decision-making consultation system, and can also guide the research and development of new drugs. The establishment of the

smart computing expert workstation and the big health technology R&D and application innovation platform will provide a strong support platform for the transformation of precision tumor diagnosis and treatment technology, and contribute to the innovative development of clinical diagnosis and treatment technology in China.